Results 161 to 170 of about 78,686 (205)
Some of the next articles are maybe not open access.
Radiosensitization by BRAF inhibitors
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2017BackgroundIncreased skin toxicity during combination therapy with a BRAF inhibitor and radiation therapy has recently been reported.Material and MethodsWe present seven melanoma patients with non‐resectable stage III or IV disease and concomitant treatment with a BRAF inhibitor and radiation therapy.ResultsIn all patients, combination therapy yielded a
Strobel, Sophia Boyoung +5 more
openaire +3 more sources
Overcoming Drug Resistance to BRAF Inhibitor
Bulletin of Mathematical Biology, 2020One of the most frequently found mutations in human melanomas is in the B-raf gene, making its protein BRAF a key target for therapy. However, in patients treated with BRAF inhibitor (BRAFi), although the response is very good at first, relapse occurs within 6 months, on the average.
Friedman, Avner, Siewe, Nourridine
openaire +2 more sources
Ophthalmic adverse effects of BRAF inhibitors
European Journal of Ophthalmology, 2022To determine the frequency, characteristics, and clinical course of ophthalmic side effects associated with systemic BRAF inhibitor therapy. Medical records of patients taking BRAF inhibitors for the treatment of systemic malignances at Mayo Clinic, Rochester from 01/01/2010 to 08/30/2021, were retrospectively reviewed.
Clara M. Castillejo Becerra +2 more
openaire +2 more sources
Best Practice & Research Clinical Haematology, 2015
Targeted treatment approaches are transforming the therapeutic landscape of cancer care. The discovery of the BRAF V600E mutation in most cases of classical hairy cell leukemia opens up unique opportunities for tumor specific treatment of HCL targeting the MEK/ERK signaling pathway.
Sascha, Dietrich, Thorsten, Zenz
openaire +2 more sources
Targeted treatment approaches are transforming the therapeutic landscape of cancer care. The discovery of the BRAF V600E mutation in most cases of classical hairy cell leukemia opens up unique opportunities for tumor specific treatment of HCL targeting the MEK/ERK signaling pathway.
Sascha, Dietrich, Thorsten, Zenz
openaire +2 more sources
Emerging BRAF inhibitors for melanoma
Expert Opinion on Emerging Drugs, 2013The clinical activity of BRAF inhibitor (BRAF-I) therapy is a major breakthrough in the treatment of metastatic melanoma carrying BRAF mutations. However, the therapeutic efficacy of BRAF-I therapy is limited due to the onset of intrinsic and acquired drug resistance.The role of wild-type BRAF in melanocytes and of the mutated BRAF in the pathogenesis ...
Sabbatino, Francesco +4 more
openaire +2 more sources
BRAF inhibitors in cancer therapy
Pharmacology & Therapeutics, 2014Activating BRAF mutations, leading to constitutive activation of the MAPK signaling pathway, are common in a variety of human cancers. Several small molecule BRAF inhibitors have been developed during the last years and shown promising results in clinical trials, especially for metastatic melanoma, while they have been less effective in colon cancer ...
Carolina, Hertzman Johansson +1 more
openaire +2 more sources
The Cancer Journal, 2011
Selective BRAF inhibitors have recently emerged as a new standard treatment for patients with metastatic melanoma harboring activating BRAF mutations. Inhibition of the MAP kinase pathway and initial evidence of antitumor effects are very reliably observed. However, many patients experience short-lived responses, whereas others are durable.
openaire +2 more sources
Selective BRAF inhibitors have recently emerged as a new standard treatment for patients with metastatic melanoma harboring activating BRAF mutations. Inhibition of the MAP kinase pathway and initial evidence of antitumor effects are very reliably observed. However, many patients experience short-lived responses, whereas others are durable.
openaire +2 more sources
Overcoming metastatic melanoma with BRAF inhibitors
Archives of Pharmacal Research, 2011Melanoma has the capacity to spread via the blood stream to the brain, and has been notoriously resistant to drug therapy. An activating mutation in the gene encoding BRAF is known to be responsible for half of melanomas. This article provides a review of GSK2118436 and PLX4032 as potential therapeutics for the treatment of melanomas by inhibiting ...
Seunghee, Hong +2 more
openaire +2 more sources
BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors
Expert Opinion on Investigational Drugs, 2015Primary neuroepithelial brain tumors encompass a wide variety of glial and glioneuronal neoplasms. Malignant tumors, tumors located in surgically inaccessible locations (e.g., eloquent brain areas, deep structures, brain stem) and recurrent or progressive tumors pose considerable treatment challenges and are candidates for novel therapeutics based on ...
Matthias, Preusser +2 more
openaire +2 more sources